RxDoctor Payments Data

Abby Lauer, MD

Internal Medicine · Southgate, KYNPI 1902339294

Payments from drug & device makers

$4,407in general payments, 2019–2025

Across 238 payments — averaging $18.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Lilly USA, LLC$924
  • Novo Nordisk$508
  • GSK$418
  • Axsome Therapeutics, Inc.$299
  • Pfizer$208
  • plus $969 from 17 others

What the payments were for

  • Food & beverage$4,407100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,407 in reported general payments places this provider in the 85th percentile of 1,284 internal medicine providers in Kentucky.

See all internal medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$66,284
Medicare patients
200
Services billed
974

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide111$145,257
MounjaroTirzepatide103$108,425
EliquisApixaban94$81,251
JardianceEmpagliflozin41$55,351
Trelegy ElliptaFluticasone/Umeclidin/Vilanter50$47,904
FarxigaDapagliflozin Propanediol32$34,609
TrulicityDulaglutide29$32,822
JanuviaSitagliptin Phosphate25$23,729
RybelsusSemaglutide20$22,396
Combivent RespimatIpratropium/Albuterol Sulfate17$12,780
VascepaIcosapent Ethyl22$12,440
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$11,184
LinzessLinaclotide12$9,381
SymbicortBudesonide/Formoterol Fumarate21$8,318
Albuterol Sulfate HfaAlbuterol Sulfate220$7,013

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$508$167,653131 claims
Lilly USA, LLCMounjaro, Trulicity$924$141,248132 claims
PfizerEliquis$208$81,25194 claims
Boehringer IngelheimJardiance, Combivent Respimat$96$68,13158 claims
GSKTrelegy Ellipta$418$47,90450 claims
MerckJanuvia, Janumet$30$30,26136 claims
AbbVieLinzess$1,080$9,38112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,284 internal medicine providers in Kentucky.

Other internal medicine in Southgate

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →